文献速递生殖医学

程序化冻融胚胎移植周期中口服、阴道或肌内黄体酮:一项先导性随机对照试验

Oral, vaginal or intramuscular progesterone in programmed frozen embryo transfer cycles: a pilot randomized controlled trial.
PubMed 文献 · Reprod Biomed Online · 2022-07-07

本研究为随机、平行、IV期先导试验,151名接受激素替代准备内膜的冻融胚胎移植女性随机分入口服地屈孕酮40mg/日组(n=52)、8%黄体酮阴道凝胶180mg/日组(n=55)或肌内黄体酮100mg/日组(n=44),移植后继续黄体支持5天。三组持续妊娠率(40.4%、38.2%、45.5%,P=0.76)和活产率(40.4%、38.2%、43.2%,P=0.61)统计学相似,肌内黄体酮组至少一种副作用及中重度副作用显著更多(P<0.001)。

要点

  • 口服地屈孕酮40mg/日、阴道凝胶180mg/日或肌内黄体酮100mg/日的持续妊娠率与活产率统计学相似。
  • 肌内黄体酮组至少一种副作用及中重度副作用的发生显著多于其他两组(P<0.001)。
  • 三种黄体支持途径在程序化冻融胚胎移植周期中生殖结局相似,但肌内途径副作用更频繁。

核心结论

  • 40mg/日口服地屈孕酮、180mg/日黄体酮阴道凝胶或100mg/日肌内黄体酮在程序化冻融胚胎移植周期中呈现相似的生殖结局,肌内黄体酮组副作用显著更频繁。

研究设计与样本

  • 随机、平行、IV期先导试验,于一家三级私立体外受精中心开展(NCT03948022)。
  • 纳入至少有一枚自体冻存囊胚的女性,经雌二醇准备内膜后随机分为三组。
  • 口服地屈孕酮组52例,总日剂量40mg;8%黄体酮阴道凝胶组55例,总日剂量180mg;肌内黄体酮组44例,50mg/ml油剂,总日剂量100mg。
  • 黄体支持5天后移植1或2枚玻璃化复苏囊胚。

主要发现

  • 三组基线人口学特征与胚胎学数据具有可比性。
  • 持续妊娠率:地屈孕酮组40.4%、阴道凝胶组38.2%、肌内黄体酮组45.5%(P=0.76),统计学相似。
  • 活产率:地屈孕酮组40.4%、阴道凝胶组38.2%、肌内黄体酮组43.2%(P=0.61),统计学相似。
  • 生化妊娠率与临床流产率在三组间亦统计学相似。
  • 肌内黄体酮组至少一种副作用及中重度副作用的发生显著多于其他两组(P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: What should be the optimal route of luteal support in programmed frozen embryo transfer (FET) cycles? DESIGN: This was a randomized, parallel, phase IV pilot trial with three groups of women undergoing FET along with hormone replacement therapy for endometrial preparation at a tertiary private IVF centre (NCT03948022). Women with at least one autologous cryopreserved blastocyst were included. After preparing the endometrium with oestradiol, 151 women were randomly assigned to one of the following three progesterone arms before embryo transfer: oral (10 mg) dydrogesterone (DYD), total daily dose 40 mg (n = 52); 8% (90 mg) progesterone vaginal gel (VAG), total daily dose 180 mg (n = 55); or intramuscular progesterone (IMP) 50 mg/ml in oil, total daily dose 100 mg (n = 44). One or two vitrified-warmed blastocysts were transferred after 5 days' progesterone support. RESULTS: Baseline demographic features and embryological data were comparable among the groups. Ongoing pregnancy rates (40.4%, 38.2% and 45.5% in the DYD, VAG and IMP arms; P = 0.76) and live birth rates (40.4%, 38.2% and 43.2% in the DYD, VAG and IMP arms, P = 0.61) were statistically similar. Biochemical pregnancy rates and clinical miscarriage rates were also statistically similar among the groups. Significantly more patients with at least one side effect and moderate-to-severe side effects were documented in the IMP arm than the other groups (P < 0.001). CONCLUSIONS: Treatment with 40 mg/day oral DYD, 180 mg/day progesterone VAG gel or 100 mg/day IMP revealed similar reproductive outcomes in programmed FET cycles. Side effects were significantly more frequent in the IMP arm.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Pabuccu E, Kovanci E, Israfilova G, et al. Oral, vaginal or intramuscular progesterone in programmed frozen embryo transfer cycles: a pilot randomized controlled trial. Reprod Biomed Online. 2022. PMID: 36153226. doi:10.1016/j.rbmo.2022.06.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。